Selinexor, a First-In-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients With Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Blood - United States
doi 10.1182/blood-2018-99-113840
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Expanded Safety Analysis of Pevonedistat, a First-In-Class NEDD8-activating Enzyme Inhibitor, in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Blood Cancer Journal
OncologyHematology
2017English

Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma

Oncotarget
Oncology
2016English

Hypomethylating Agents in Combination With Histone Deacetylase Inhibitors in Higher Risk Myelodysplastic Syndromes: Is There a Light at the End of the Tunnel?

Cancer
Cancer ResearchOncology
2017English

Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes

Seminars in Oncology
OncologyHematology
2011English

Transplantation for Myelodysplastic Syndrome in the Era of Hypomethylating Agents

Current Opinion in Hematology
Hematology
2012English

A Novel Clofarabine Bridge Strategy Facilitates Allogeneic Transplantation in Patients With Relapsed/Refractory Leukemia and High-Risk Myelodysplastic Syndromes

Bone Marrow Transplantation
TransplantationHematology
2013English

Hematologic Responses to Deferasirox Therapy in Transfusion-Dependent Patients With Myelodysplastic Syndromes

Haematologica
Hematology
2012English

Landscape of Genetic Lesions in 944 Patients With Myelodysplastic Syndromes

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Improving Prognostic Tools for Patients With Myelodysplastic Syndromes

Mayo Clinic Proceedings
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy